A breakthrough solution for long-term intrinsic clearance studies of low-clearance drugs
A major goal in the pharmaceutical industry is the development of "low-clearance" drugs: compounds that are metabolized slowly to extend their half-life and minimize dosing frequency. To date, these drugs are failing in the clinic, due largely to the limited predictive power of existing in vitro model systems.
In this webinar, Dr. Liz Quinn of Takara Bio USA, Inc. presents data demonstrating an improved in vitro model system using our Cellartis Power Primary HEP Medium. This novel medium enables the culture of human primary hepatocytes for up to 4 weeks, allowing long-term incubation without a medium change (up to 10 days) to accurately predict in vivo intrinsic clearance.
- Challenges of developing low-clearance drugs
- Pharmacokinetics and the liver's role in drug metabolism
- Limitations of existing in vitro models for predicting in vivo intrinsic clearances
- Advantages of Cellartis Power Primary HEP Medium for primary hepatocyte culture
- Demonstration of Cellartis Power Primary HEP Medium in a long-term intrinsic clearance study
Sign up to watch the webinar now
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2020 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.